Dr. Carlos Rodriguez-Galindo, MD
Claim this profileSt. Jude Children's Research Hospital
Studies Retinoblastoma
Studies Cataract
3 reported clinical trials
9 drugs studied
Area of expertise
1Retinoblastoma
Stage I
Stage II
2Cataract
Affiliated Hospitals
Clinical Trials Carlos Rodriguez-Galindo, MD is currently running
Smartphone App Detection
for Retinoblastoma
This trial is testing a smartphone app called CRADLE to help detect leukocoria in children. The app takes pictures of the eyes and looks for signs of this condition. It aims to improve early detection in kids who have or might have serious eye diseases.
Recruiting1 award N/A
Intraocular Chemotherapy
for Retinoblastoma
This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB). RB is a type of cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). It may be hereditary or nonhereditary (sporadic). RB is considered harder to treat (higher risk) when there are vitreous seeds present. Vitreous seeds are RB tumors in the jelly-like fluid of the eye (called the vitreous humor). The term, risk, refers to the chance of the cancer not responding to treatment or coming back after treatment. Melphalan is in a class of medications called alkylating agents. It may kill cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Other chemotherapy drugs given during this trial include carboplatin, vincristine, and etoposide. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Adding melphalan to standard chemotherapy early in treatment may improve the ability to treat vitreous seeds and may be better than standard chemotherapy alone in treating retinoblastoma.
Recruiting1 award Phase 2
More about Carlos Rodriguez-Galindo, MD
Clinical Trial Related11 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Carlos Rodriguez-Galindo, MD has experience with
- Carboplatin
- Enucleation
- External Beam Radiation
- Focal Therapy
- Proton Beam Radiation
- Topotecan
Breakdown of trials Carlos Rodriguez-Galindo, MD has run
Retinoblastoma
SENSIMED Triggerfish in Glaucoma Patients
Congenital Cataract
Developmental Glaucoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carlos Rodriguez-Galindo, MD specialize in?
Carlos Rodriguez-Galindo, MD focuses on Retinoblastoma and Cataract. In particular, much of their work with Retinoblastoma has involved Stage I patients, or patients who are Stage II.
Is Carlos Rodriguez-Galindo, MD currently recruiting for clinical trials?
Yes, Carlos Rodriguez-Galindo, MD is currently recruiting for 2 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Carlos Rodriguez-Galindo, MD has studied deeply?
Yes, Carlos Rodriguez-Galindo, MD has studied treatments such as Carboplatin, Enucleation, External Beam Radiation.
What is the best way to schedule an appointment with Carlos Rodriguez-Galindo, MD?
Apply for one of the trials that Carlos Rodriguez-Galindo, MD is conducting.
What is the office address of Carlos Rodriguez-Galindo, MD?
The office of Carlos Rodriguez-Galindo, MD is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.